Santosh Kesari

Santosh Kesari

Company: Curtana Pharmaceuticals

Job title: Co-founder


Targeting OLIG2 in GBM and Medulloblastoma Using CT-179, an Orally Delivered Small Molecule Entering Clinical Development 2:15 pm

Scientific rationale for targeting OLIG2 in GBM, medulloblastoma, and other gliomas Preclinical data supporting the use of CT-179 alone and in combination with standard of care therapies Overview of the early-stage clinical development plan for CT-179 in adults with recurrent and newly diagnosed GBMRead more

day: Conference Day Two

9:00am -12:00pm Morning Workshop A: Optimizing Clinical Trial Design: From Biomarker Selection to Imaging to Endpoints 9:00 am - 12:00 pm

Many therapies show huge promise for glioblastoma treatment, but few have been successful in clinical trials. A key challenge associated with drug discovery in the space is designing efficient and effective trials, which grows increasingly more difficult with the adoption of combination approaches. This workshop will cover: Formulating an adaptive trial design Next generation combination…Read more

day: Pre-conference Workshop Day

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.